US$ 28.73
flow trial semaglutide kidney outcomes 2024 nejm hazard ratio Effects of Once-Weekly on Disease by KDIGO Risk Category in the SUSTAIN 6 Semaglutide in CKD - The
Description
Treatment history and rationale guide decision-making

We begin with the scientific background tracing the incretin concept from early 20th-century experiments through the discovery of GLP-1 in the 1980s

history of blood diseases

doi: 10.1016/0092-8674(95)90013-6 54 BacchettaRBarzaghiFRoncaroloMG

The datasets are not included in the article or Supplementary Material